Total lesion glycolysis as an IgG4-related disease activity marker

References

• Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD),2011. Mod Rheumatol.2012;22(1):21–30.
   Web of Science ®Google Scholar
• Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181–92.
   PubMed Web of Science ®Google Scholar
• Uchida K, Masamune A, Shimosegawa T, Okazaki K. Prevalence of IgG4-related disease in japan based on nationwide survey in2009. Int J Rheumatol.2012;2012:1–5.
   Google Scholar
• Ebbo M, Grados A, Guedj E, Gobert D, Colavolpe C, Zaidan M, et al. Usefulness of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography for staging and evaluation of treatment response in IgG4-related disease: a retrospective multicenter study. Arthritis Care Res (Hoboken). 2014;66(1):86–96.
   PubMedGoogle Scholar
• Nakatani K, Nakamoto Y, Togashi K. Utility of FDG PET/CT in IgG4-related systemic disease. Clin Radiol. 2012;67(4):297–305.
   PubMedGoogle Scholar
• Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin. Positron Imaging. 1999;2(3):159–71.
   PubMedGoogle Scholar
• Lee P, Weerasuriya DK, Lavori PW, Quon A, Hara W, Maxim PG, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007;69(2):328–33.
   PubMedGoogle Scholar
• Chung MK, Jeong HS, Park SG, Jang JY, Son YI, Choi JY, et al. Metabolic tumor volume of [18F]-Fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res. 2009;15:5861–8.
   PubMed Web of Science ®Google Scholar
• Seol YM, Kwon BR, Song MK, Choi YJ, Shin HJ, Chung JS, et al. Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy. Acta Oncol. 2010;49(2):201–8.
   PubMedGoogle Scholar
• Ryu IS, Kim JS, Roh J-L, Cho K-J, Choi S-H, Nam SY, et al. Prognostic significance of preoperative metabolic tumour volume and total lesion glycolysis measured by 18F-FDG PET/CT in squamous cell carcinoma of the oral cavity. Eur J Nucl Med Mol Imaging. 2013;41(3):4521–61.
   Google Scholar
• Khosroshahi A, Carruthers MN, Deshpande V, Unizony S, Bloch DB, Stone JH. Rituximab for the treatment of IgG4-related disease. Medicine. 2012;91(1):57–66.
   PubMedGoogle Scholar
• Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant. 2007;40:381–7.
   PubMed Web of Science ®Google Scholar
• EZR_HP. http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmed.html;2013 Oct pp. 1–1. Report No.: Accessed on 2013 Oct 1.
   Google Scholar
• Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol. 2012;22(1):1–14.
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Yamamoto M, Naishiro Y, Sudoh G, Ishigami K, Yajima H, et al. Necessity of early intervention for IgG4-related disease–delayed treatment induces fibrosis progression. Rheumatology. 2013;52(4):679–83.
   PubMed Web of Science ®Google Scholar
• Carruthers MN, Stone JH, Deshpande V, Khosroshahi A. Development of an IgG4-RD Responder Index. Int J Rheumatol. 2012;2012:259408.
   PubMedGoogle Scholar
• Ebbo M, Daniel L, Pavic M, Sève P, Hamidou M, Andres E, et al. IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. Medicine. 2012;91(1):49–56.
   PubMedGoogle Scholar
• Signore A, Glaudemans AWJM. The molecular imaging approach to image infections and inflammation by nuclear medicine techniques. Ann Nucl Med. 2011;25(10):681–700.
   PubMedGoogle Scholar
• Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995;36(7):1301–6.
   PubMedGoogle Scholar
• Ishimori T, Saga T, Mamede M, Kobayashi H, Higashi T, Nakamoto Y, et al. Increased 18F-FDG uptake in a model of inflammation: concanavalin A-mediated lymphocyte activation. J Nucl Med. 2002;43:658–63.
   PubMed Web of Science ®Google Scholar
• Weber WA, Schwaiger M, Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol. 2000;27(7): 683–7.
   PubMedGoogle Scholar
• Cheng Y, Lv N, Wang Z, Chen B, Dang A. 18-FDG-PET in assessing disease activity in Takayasu arteritis: a meta-analysis. Clin Exp Rheumatol. 2013;31(1 Suppl 75):S22–7.
   PubMed Web of Science ®Google Scholar
• Wang S-C, Xie Q, Lv W-F. Positron emission tomography/computed tomography imaging and rheumatoid arthritis. Int J Rheum Dis. 2014;17(3):248–55.
   PubMedGoogle Scholar
• Santhosh S, Mittal BR, Gayana S, Bhattacharya A, Sharma A, Jain S. F-18 FDG PET/CT in the evaluation of Takayasu arteritis: An experience from the tropics. J Nucl Cardiol. 2014;21(5): 993–1000.
   PubMed Web of Science ®Google Scholar
• Smith MF, Hiepe F, Dörner T, Burmester G. Biomarkers as tools for improved diagnostic and therapeutic monitoring in systemic lupus erythematosis. Arthritis Res Ther. 2009;11(6):255.
   PubMedGoogle Scholar
• Junghans RP, Waldmann TA. Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. J Exp Med. 1996; 183(4):1587–602.
   PubMedGoogle Scholar
• Vorselaars ADM, Verwoerd A, Van Moorsel CHM, Keijsers RGM, Rijkers GT, Grutters JC. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. Eur Respir J. 2014;43: 602–9.
   PubMed Web of Science ®Google Scholar
• Okazaki K, Uchida K, Koyabu M, Miyoshi H, Takaoka M. Recent advances in the concept and diagnosis of autoimmune pancreatitis and IgG4-related disease. J Gastroenterol. 2011;46:277–88.
   PubMed Web of Science ®Google Scholar
• Matsubayashi H, Uesaka K, Kanemoto H, Asakura K, Kakushima N, Tanaka M, et al. Soluble IL-2 receptor, a new marker for autoimmune pancreatitis. Pancreas. 2012;41(3):493–6.
   PubMedGoogle Scholar
• Tabata T, Kamisawa T, Takuma K, Egawa N, Setoguchi K, Tsuruta K, et al. Serial changes of elevated serum IgG4 levels in IgG4-related systemic disease. Intern Med. 2011;50(2):69–75.
   PubMed Web of Science ®Google Scholar
• Zen Y, Nakanuma Y. IgG4-related disease: a cross-sectional study of 114 cases. Am. J Surg Pathol. 2010;34(12):1812–9.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Tabeya T, Naishiro Y, Yajima H, Ishigami K, Shimizu Y, et al. Value of serum IgG4 in the diagnosis of IgG4-related disease and in differentiation from rheumatic diseases and other diseases. Mod Rheumatol. 2011;22(3):419–25.
   PubMedGoogle Scholar
• Ryuko H, Otsuka F. A comprehensive analysis of 174 febrile patients admitted to Okayama University Hospital. Acta Med Okayama. 2013;67(4):227–37.
   PubMedGoogle Scholar